Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).
about
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Radionuclide Therapy for Neuroendocrine Tumors.Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.Exploiting induced senescence in intestinal organoids to drive enteroendocrine cell expansion.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.Re: Palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasementThe difference between medicine and magic is that magicians know what they are doingENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q33435622-9077FF60-1AB5-43D8-9A8D-61A957A426DFQ33588174-A8CBCCB9-20BB-486F-A936-6160F40679D9Q38711101-EA64CAC8-650A-47ED-96A2-4A0EFED34B29Q39144880-04702F39-6D9C-4FD3-B705-933A96773CB9Q42001885-B1F729E4-DFAE-4709-AA2B-A40E31C861BAQ42342131-D904F53C-8DDE-4B3E-99E6-EFC8AAF4AE37Q50143284-9992F14A-72D0-491A-AF3A-24568DE15842Q57758740-7FFAB69C-7119-4ED0-B19C-37CEF0431CFDQ57758762-EC31B5B6-543B-4F8D-96D2-ABB48C1F63EEQ57990732-0314B987-D6E0-45E5-93E9-FADBD394C7B6
P2860
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@ast
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@en
Assessment of predictors of re ...... ptor chemoradionuclide therapy
@nl
type
label
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@ast
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@en
Assessment of predictors of re ...... ptor chemoradionuclide therapy
@nl
prefLabel
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@ast
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@en
Assessment of predictors of re ...... ptor chemoradionuclide therapy
@nl
P2093
P2860
P1476
Assessment of predictors of re ...... oradionuclide therapy (PRCRT).
@en
P2093
A Herschtal
M S Hofman
M Thompson
V Johnston
P2860
P2888
P304
P356
10.1007/S00259-014-2788-5
P577
2014-05-21T00:00:00Z